{
    "clinical_study": {
        "@rank": "94118", 
        "acronym": "MATCHBOX", 
        "arm_group": [
            {
                "arm_group_label": "BAY Factor VII (6.5 \u00b5g/kg) / Placebo", 
                "arm_group_type": "Experimental", 
                "description": "n = 4, randomized 3:1; 6.5 \u00b5g/kg BAY 86-6150 (B0189):Placebo"
            }, 
            {
                "arm_group_label": "BAY Factor VII (20 \u00b5g/kg) / Placebo", 
                "arm_group_type": "Experimental", 
                "description": "n = 4, randomized 3:1; 20 \u00b5g/kg BAY 86-6150 (B0189):Placebo"
            }, 
            {
                "arm_group_label": "BAY Factor VII (50 \u00b5g/kg) / Placebo", 
                "arm_group_type": "Experimental", 
                "description": "n = 4, randomized 3:1; 50 \u00b5g/kg BAY 86-6150 (B0189):Placebo"
            }, 
            {
                "arm_group_label": "BAY Factor VII (90 \u00b5g/kg) / Placebo", 
                "arm_group_type": "Experimental", 
                "description": "n = 4, randomized 3:1; 90 \u00b5g/kg BAY 86-6150 (B0189):Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is the first in humans study of BAY86-6150  (B0189) in non-bleeding subjects with\n      moderate or severe congenital hemophilia A or B with or without inhibitors. This is a\n      randomized, double-blind, placebo-controlled, single-dose, dose escalation study. It is\n      designed to investigate the safety, tolerability, potential immunogenicity, pharmacokinetic\n      and pharmacodynamic profile of BAY86-6150 (B0189) and to determine a dose or range of doses\n      to be examined in subsequent studies."
        }, 
        "brief_title": "Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hemophilia A", 
            "Hemophilia B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemophilia B", 
                "Hemophilia A"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of moderate or severe congenital hemophilia A or B with or without inhibitors\n             to Factor VIII (FVIII) or Factor IX (FIX)\n\n          -  Male subjects 18-65 years of age inclusive\n\n          -  Able to dismiss factor replacement therapy during the course of the study unless\n             required for the treatment of an acute bleeding episode\n\n          -  Written informed consent\n\n          -  Willing and able to comply with the requirements of the protocol\n\n          -  Have adequate venous access\n\n          -  Willing to use an effective method of contraception until Day 30 of their study\n             participation\n\n        Exclusion Criteria:\n\n          -  Received factor replacement therapy or treatment with any other procoagulant\n             therapeutics, or any antifibrinolytic agents, including blood products, at anytime\n             within 5 days prior to administration of investigational medicinal product (IMP)\n\n          -  Planned administration of factor replacement therapy or treatment with any other\n             procoagulant therapeutics or any antifibrinolytic agents, including blood products,\n             at anytime during the study period\n\n          -  Acute bleeding episode or any ongoing bleeding episode at any time within 7 days\n             prior to administration IMP\n\n          -  Clinically relevant coagulation disorder other than congenital hemophilia A or B\n\n          -  History of angina or receiving treatment for angina\n\n          -  History of coronary atherosclerotic disease, disseminated intravascular coagulopathy,\n             or stage 2 hypertension defined as systolic blood pressure (SBP) >/= 160 mmHg or\n             diastolic blood pressure (DBP) >/= 90 mmHg\n\n          -  History of transient ischemic attack, stroke, myocardial infarction, coronary artery\n             disease, congestive heart failure, or thromboembolic event\n\n          -  Active infection on day of IMP administration or septicemia at any time within 30\n             days prior to administration of IMP"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921855", 
            "org_study_id": "13787", 
            "secondary_id": "2008-000117-29"
        }, 
        "intervention": [
            {
                "arm_group_label": "BAY Factor VII (6.5 \u00b5g/kg) / Placebo", 
                "description": "BAY Factor VII (BAY86-6150), 6.5 \u00b5g/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.", 
                "intervention_name": "BAY Factor VII (BAY86-6150)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY Factor VII (20 \u00b5g/kg) / Placebo", 
                "description": "BAY Factor VII (BAY86-6150), 20 \u00b5g/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.", 
                "intervention_name": "BAY Factor VII (BAY86-6150)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY Factor VII (50 \u00b5g/kg) / Placebo", 
                "description": "BAY Factor VII (BAY86-6150), 50 \u00b5g/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.", 
                "intervention_name": "BAY Factor VII (BAY86-6150)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAY Factor VII (90 \u00b5g/kg) / Placebo", 
                "description": "BAY Factor VII (BAY86-6150), 90 \u00b5g/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.", 
                "intervention_name": "BAY Factor VII (BAY86-6150)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BAY Factor VII (6.5 \u00b5g/kg) / Placebo", 
                    "BAY Factor VII (20 \u00b5g/kg) / Placebo", 
                    "BAY Factor VII (50 \u00b5g/kg) / Placebo", 
                    "BAY Factor VII (90 \u00b5g/kg) / Placebo"
                ], 
                "description": "Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 9, 2013", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "zip": "02-776"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa", 
                        "state": "Freestate", 
                        "zip": "9300"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "2193"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W12 0HS"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Poland", 
                "South Africa", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "South Africa: Medicines Control Council", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 50"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic assessment, based on plasma concentration of BAY86-6150", 
                "safety_issue": "No", 
                "time_frame": "9 time points from pre-dosing on Day 1 up to 48 hours post-dosing"
            }, 
            {
                "measure": "Pharmacodynamic assessment, based on plasma hemostasis marker level", 
                "safety_issue": "No", 
                "time_frame": "9 time points from pre-dosing on Day 1 up to 48 hours post-dosing"
            }, 
            {
                "measure": "Immunogenicity assessment, based on anti-BAY86-6150 binding antibody levels", 
                "safety_issue": "Yes", 
                "time_frame": "3 time points from pre-dosing on Day 1 up to Day 50"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}